Kazia Therapeutics Limited   Report issue

For profit Phase 1 Phase 2
Founded: Sydney Australia (1994)

Organization Overview

First Clinical Trial
2001
NCT00022295
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Kazia Therapeutics | Kazia Therapeutics Limited | Novogen Ltd

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Neoplasms (Phase 1)

Breast Neoplasms (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Central Nervous System Neoplasms (Phase 1)

Fallopian Tube Neoplasms (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 1)

Meningeal Carcinomatosis (Phase 1)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 1)

Neoplasms, Second Primary (Phase 1)

Nervous System Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 2)

Peritoneal Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 11
  • # of Trial APIs: 8